Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Danvatirsen or AZD5069 in Advanced Solid Tumors and SCCHN
NCT02499328Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2015
- Primary completion
- Feb 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
A Phase 2 trial of danvatirsen, azd5069 in solid tumor (advanced stage), squamous cell carcinoma of the head and neck (HNSCC), sponsored by AstraZeneca. Started Aug 2015; status: completed.
02
Drugs
danvatirsenazd5069
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02499328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499328.